Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Which depressed patients respond to nefazodone and when?
Autore:
Trivedi, MH; Rush, AJ; Pan, JY; Carmody, TJ;
Indirizzi:
Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75235 USA Univ Texas Dallas TX USA 75235 d Ctr, Dept Psychiat, Dallas, TX 75235 USA Sun Yat Sen Univ Med Sci, Third Hosp, Dept Psychiat, Guangzhou, Peoples R China Sun Yat Sen Univ Med Sci Guangzhou Peoples R China hou, Peoples R China Univ Texas, SW Med Ctr, Acad Comp Serv, Dallas, TX USA Univ Texas Dallas TX USA xas, SW Med Ctr, Acad Comp Serv, Dallas, TX USA
Titolo Testata:
JOURNAL OF CLINICAL PSYCHIATRY
fascicolo: 3, volume: 62, anno: 2001,
pagine: 158 - 163
SICI:
0160-6689(200103)62:3<158:WDPRTN>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
MEDICATION ALGORITHM PROJECT; TRUE DRUG RESPONSE; MAJOR DEPRESSION; DOUBLE-BLIND; FLUOXETINE TREATMENT; SYMPTOMATOLOGY IDS; PATTERN-ANALYSIS; ANTIDEPRESSANT; SERTRALINE; TRIAL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
47
Recensione:
Indirizzi per estratti:
Indirizzo: Trivedi, MH Univ Texas, SW Med Ctr, Dept Psychiat, St Paul POB 1,5959 Harry Hines Blvd,Suite 520, Dallas, TX 75235 USA Univ Texas St Paul POB 1,5959 Harry Hines Blvd,Suite 520 Dallas TX USA 75235
Citazione:
M.H. Trivedi et al., "Which depressed patients respond to nefazodone and when?", J CLIN PSY, 62(3), 2001, pp. 158-163

Abstract

Background: Retrospective data analyses were conducted of a single-blind trial of 993 outpatients with nonpsychotic major depression (DSM-III-R) treated for 12 weeks with nefazodone to provide a more specific picture of the nature and timing of response or remission to acute-phase treatment. Method: All patients participated in a single-blind, 16-week lead-in to obtain responders eligible for a subsequent double-blind, randomized continuation phase trial. Outcomes were defined by the 17-item Hamilton Rating Scale for Depression (HAM-D). A greater than or equal to 50% reduction from baseline defined response, and a total HAM-D exit score of less than or equal to 8 defined remission. Results: Of all patients who entered the trial, 41.8% (last observation carried forward) responded at or before week 4 (early responders), and an additional 25.2% responded thereafter. 18.3% achieved remission at or before week 4; 33.6% achieved remission after week 4. Thus, 77.3% of those responding ultimately remitted. On average, remission followed response by 2 weeks. The average end-of-treatment dose was 376 mg/day at exit (last observationcurried for ward). Responders or remitters (as opposed to nonresponders ornonremitters) had lower baseline depressive symptomatology and were more likely to be married or cohabiting. Conclusion: The full symptomatic benefit of antidepressant medication may not be apparent until completion of an 8- to 10-week trial. A high number of responders ultimately attained remission. Baseline demographic and clinical features were not highly predictive of who would or would not benefit from nefazodone. For routine care, a minimal acute-phase trial, using a 50% reduction in baseline symptom severity to define response, should be 8 weeks. Whether ultimate nonresponders can be identified earlier than 8 weeks deserves further study.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/05/20 alle ore 13:31:45